TRPV1 and cardiac hypertrophy: The subcutaneous administration of the TRPV1 inhibitor, BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide), reduced cardiac hypertrophy and HF in vivo [168].